| |
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today.
|
|
Today’s Big NewsMay 13, 2025 |
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now.
|
|
| By Nick Paul Taylor GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations. |
|
|
|
By Kevin Dunleavy Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbuster Xarelto in the first quarter. |
By Conor Hale The announcement follows a five-year, $50-billion commitment from the Swiss pharma to expand its U.S. footprints in R&D and production. |
By Nick Paul Taylor Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral birth control pill in a presentation, triggering an untitled letter. |
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more.
|
|
By Ben Adams,Gabrielle Masson San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. |
By Angus Liu Bluebird bio shareholders have dragged their feet in tendering shares as part of the company's sale process, prompting buyers Carlyle and SK Capital to extend their offer once again. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Fraiser Kansteiner Novo Nordisk has unveiled data from the phase 3 REAL8 trial, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor, Norditropin, in a trio of growth disorders in kids. |
By Andrea Park Perhaps no literary genre has made quite as big of a splash in recent years as the fantasy-romance segment, colloquially known as “romantasy”—a phenomenon that Organon is capitalizing on in its newest ad campaign. |
By Zoey Becker After a decade of follow-up, Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer. |
By Darren Incorvaia The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that has already been cut, according to a May 13 statement from the Joint Task Force to Combat Anti-Semitism. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," Angela Hwang reflects on her leap from nearly 30 years at Pfizer to leading a biotech startup—and the career lessons that continue to guide her leadership and commitment to developing diverse talent. |
|
|---|
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
